Removing Neumann is a difficult decision for Son, who has long believed in WeWork and Neumann's vision to quickly expand the company.Technologyread more
The Kingdom and oil and gas industry have been slow to shore up defenses, raising red flags about the possibility of longer term fall-out in the region.Technologyread more
Datadog went public on Thursday and instantly hit a $10 billion valuation, becoming the fourth cloud software debut to reach that level this year.Technologyread more
There are challenges with Iran, North Korea, the Afghan Taliban, Israel and the Palestinians — not to mention a number of trade pacts.Politicsread more
Blackstone Executive Vice Chairman Tony James says he's less optimistic now than before that the U.S.-China trade war could be resolved, but even a smaller deal could help...World Economyread more
In his new memoir, "The Ride of a Lifetime," Iger explains why he decided against the deal to buy Twitter.Technologyread more
In perhaps Buffett's first televised profile, he explained a method of investing that prioritizes bargains and makes use of an occasional baseball analogy.Marketsread more
Gluskin Sheff's David Rosenberg reinforces his recession forecast following the Federal Reserve's September meeting.Futures Nowread more
"This would be the most profound violation of the presidential oath of office certainly during this presidency," House Intelligence Chair Adam Schiff said.Politicsread more
A 58% majority of registered voters express unease about voting for Trump, but slightly more say the same about Joe Biden and Bernie Sanders, while Elizabeth Warren fares only...Politicsread more
The massive market transformation this month that some on Wall Street called a "once in a decade opportunity" might have just been a one-off technical move because of taxes.Marketsread more
(Adds detail from FDA's media briefing, background on market)
July 24 (Reuters) - Allergan Plc said on Wednesday it was recalling its Biocell textured breast implants and tissue expanders across markets, citing concerns over a rare form of cancer, after the U.S. health agency asked the drugmaker to pull the products.
The Food And Drug Administration found the use of these breast implants was tied to increased risk of a rare type of cancer known as breast-implant associated anaplastic large cell lymphoma (BIA-ALCL).
"Once the evidence indicated that Allergan's product appeared to be directly linked to significant patient harm ... the FDA took action to alert the firm to new evidence and that the recall is warranted," Amy Abernethy, FDA's principal deputy commissioner, said on a media call.
Allergan has already stopped selling the Biocell textured implants in Europe and Canada.
Breast implants come in both textured and smooth formats, with the former resembling sandpaper, making it less likely to move around inside breast and change position.
Textured breast implants are more commonly used in Europe than in the United States, with it accounting for only 10% of all breast implants sold in the country.
Demand for Allergan's smooth implants may be impacted and litigation claims may rise due to the recall, Stifel analyst Annabel Samimy said, but added that a direct impact from the recall was negligible for the company, which is being bought by AbbVie Inc for $63 billion.
Other textured implants sold in the United States are made by Sientra Inc and Johnson & Johnson's Mentor unit.
The FDA has warned in the past that risk of BIA-ALCL is higher in textured implants, but the risk with Allergan's Biocell textured implants is about six times compared with textured implants from other manufacturers marketing in the United States, according to the health agency.
The FDA said 573 cases of BIA-ALCL were recorded globally as of July 6, out of which 481 patients had Allergan implants at the time of diagnosis.
Jeff Shuren, director of the FDA's Center for Devices and Radiological Health, said the FDA is still assessing if the risk of developing BIA-ALCL is limited to specific models of textured, or all textured breast implants.
Allergan said the recall, however, does not affect its Natrelle smooth or Microcell breast implants and tissue expanders. (Reporting by Nivedita Balu and Manas Mishra in Bengaluru; Editing by Shailesh Kuber and Shinjini Ganguli)